ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives $39.14 Average Target Price from Analysts

Key Points

• ArriVent BioPharma, Inc. has an average consensus rating of "Buy" from eight analysts, with a 12-month price target averaging $39.14.
• The company reported a quarterly EPS of ($0.90), missing estimates, and analysts predict a -2.74 EPS for the current fiscal year.
• Institutional investors have significantly increased their stake in ArriVent BioPharma, with Squarepoint Ops LLC raising its holdings by 1,009.1% in the latest quarter.

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report) has been given an average recommendation of "Buy" by the eight analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $39.1429.

Several research analysts have recently issued reports on AVBP shares. Wall Street Zen cut shares of ArriVent BioPharma from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. Guggenheim reiterated a "buy" rating and issued a $45.00 price objective on shares of ArriVent BioPharma in a report on Tuesday, June 24th. HC Wainwright reiterated a "buy" rating and issued a $42.00 price objective (up from $40.00) on shares of ArriVent BioPharma in a report on Tuesday, August 12th. Oppenheimer reissued an "outperform" rating and set a $44.00 target price (up from $39.00) on shares of ArriVent BioPharma in a research note on Tuesday, June 24th. Finally, B. Riley raised shares of ArriVent BioPharma to a "strong-buy" rating in a research note on Monday, August 25th.

Institutional Trading of ArriVent BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its stake in ArriVent BioPharma by 773.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,599 shares of the company's stock valued at $43,000 after purchasing an additional 1,416 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in ArriVent BioPharma by 31.0% during the second quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company's stock valued at $56,000 after purchasing an additional 609 shares during the last quarter. GAMMA Investing LLC lifted its stake in ArriVent BioPharma by 3,730.0% during the first quarter. GAMMA Investing LLC now owns 2,681 shares of the company's stock valued at $500,000 after purchasing an additional 2,611 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in ArriVent BioPharma by 571.6% during the second quarter. Tower Research Capital LLC TRC now owns 6,669 shares of the company's stock valued at $145,000 after purchasing an additional 5,676 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in ArriVent BioPharma during the fourth quarter valued at approximately $218,000. 9.48% of the stock is owned by institutional investors and hedge funds.

ArriVent BioPharma Price Performance

Shares of ArriVent BioPharma stock traded down $0.76 on Thursday, hitting $18.95. The company had a trading volume of 268,018 shares, compared to its average volume of 258,125. The business has a 50-day simple moving average of $19.90 and a 200-day simple moving average of $20.39. The company has a market cap of $768.80 million, a PE ratio of -4.71 and a beta of 1.17. ArriVent BioPharma has a 52 week low of $15.47 and a 52 week high of $36.37.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.20). On average, equities research analysts predict that ArriVent BioPharma will post -2.74 earnings per share for the current fiscal year.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.